MedTrace Logo

Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging

NCT05135312 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-01-06

No results posted yet for this study

Summary

OptiSkin is now enrolling a new study to monitor nail changes in patients with nail psoriasis treated with Enbrel® (etanercept) with optical coherence tomography (OCT).

Conditions

Interventions

DRUG

Etanercept

TNF-alpha inhibitors improve nail psoriasis.

DEVICE

OCT

Optical Coherence Tomography is a noninvasive imaging device that can be used to monitor nail disease severity.

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • OptiSkin Medical

    lead OTHER

Principal Investigators

  • Orit Markowitz, MD · OptiSkin Medical

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-09
Primary Completion
2022-08-08
Completion
2022-08-08
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05135312 on ClinicalTrials.gov